Literature DB >> 20422780

Aldosterone and inflammation.

Kimberly C Gilbert1, Nancy J Brown.   

Abstract

PURPOSE OF REVIEW: Aldosterone causes tissue inflammation leading to fibrosis and remodeling in the heart, vasculature, and kidney. We summarize recent data regarding the mechanism(s) through which aldosterone stimulates inflammation. RECENT
FINDINGS: Studies elucidate the cell-specific effects of mineralocorticoid receptor activation on inflammatory cell infiltration and adhesion, and highlight the role of the macrophage in the development of vascular collagen deposition and hypertension. Activation of nuclear factor-kappaB in vascular smooth muscle cells involves a complex interplay between the angiotensin subtype 1 (AT1) receptor and the mineralocorticoid receptor. Activation of the mineralocorticoid receptor by aldosterone stimulates an inflammatory phenotype in adipocytes and contributes to insulin resistance by increasing oxidative stress.
SUMMARY: Mechanistic studies of aldosterone-induced inflammation provide the rationale for an expanded therapeutic role for mineralocorticoid receptor antagonists and aldosterone synthase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422780      PMCID: PMC4079531          DOI: 10.1097/med.0b013e3283391989

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  56 in total

1.  Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.

Authors:  Mario Fritsch Neves; Farhad Amiri; Agostino Virdis; Quy N Diep; Ernesto L Schiffrin
Journal:  Can J Physiol Pharmacol       Date:  2005-11       Impact factor: 2.273

2.  Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

Authors:  Shigeru Shibata; Miki Nagase; Shigetaka Yoshida; Hiroshi Kawachi; Toshiro Fujita
Journal:  Hypertension       Date:  2007-01-02       Impact factor: 10.190

3.  Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase.

Authors:  Sofian Johar; Alison C Cave; Anilkumar Narayanapanicker; David J Grieve; Ajay M Shah
Journal:  FASEB J       Date:  2006-05-23       Impact factor: 5.191

4.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

5.  Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells.

Authors:  Li-Juan Min; Masaki Mogi; Jian-Mei Li; Jun Iwanami; Masaru Iwai; Masatsugu Horiuchi
Journal:  Circ Res       Date:  2005-08-04       Impact factor: 17.367

6.  Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.

Authors:  Yuki Hirono; Takanobu Yoshimoto; Noriko Suzuki; Toru Sugiyama; Maya Sakurada; Shinji Takai; Naohiko Kobayashi; Masayoshi Shichiri; Yukio Hirata
Journal:  Endocrinology       Date:  2007-01-11       Impact factor: 4.736

Review 7.  Regulation of NaCl transport in the renal collecting duct: lessons from cultured cells.

Authors:  M Bens; C Chassin; A Vandewalle
Journal:  Pflugers Arch       Date:  2006-08-26       Impact factor: 3.657

8.  Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.

Authors:  Jun Suzuki; Masaru Iwai; Masaki Mogi; Akira Oshita; Toyofumi Yoshii; Jitsuo Higaki; Masatsugu Horiuchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-01-19       Impact factor: 8.311

9.  Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling?

Authors:  Géza Fejes-Tóth; Anikó Náray-Fejes-Tóth
Journal:  Endocrinology       Date:  2007-01-18       Impact factor: 4.736

10.  Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells.

Authors:  Jun Yuan; Ruhan Jia; Yan Bao
Journal:  J Biochem Mol Biol       Date:  2007-03-31
View more
  50 in total

1.  PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice.

Authors:  Baojian Xue; Terry G Beltz; Ralph F Johnson; Fang Guo; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

2.  Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Authors:  Scott B Hoyt; Whitney Petrilli; Clare London; Gui-Bai Liang; Jim Tata; Qingzhong Hu; Lina Yin; Chris J van Koppen; Rolf W Hartmann; Mary Struthers; Tom Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Tian-Quan Cai; Sloan Stribling; Lee-Yuh Pai; Xiuying Ma; Joe Metzger; Andreas Verras; Daniel McMasters; Qing Chen; Elaine Tung; Wei Tang; Gino Salituro; Nicole Buist; Joe Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Maxwell; Mike Lassman; Theresa McLaughlin; Jose Castro-Perez; Daphne Szeto; Gail Forrest; Richard Hajdu; Mark Rosenbach; Yusheng Xiong
Journal:  ACS Med Chem Lett       Date:  2015-07-17       Impact factor: 4.345

Review 3.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

4.  Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression.

Authors:  Er-Liang Kong; Jin-Min Zhang; Ni An; Yong Tao; Wei-Feng Yu; Fei-Xiang Wu
Journal:  J Cell Commun Signal       Date:  2018-06-07       Impact factor: 5.782

5.  Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Authors:  Scott B Hoyt; Min K Park; Clare London; Yusheng Xiong; Jim Tata; D Jonathan Bennett; Andrew Cooke; Jiaqiang Cai; Emma Carswell; John Robinson; John MacLean; Lindsay Brown; Simone Belshaw; Thomas R Clarkson; Kun Liu; Gui-Bai Liang; Mary Struthers; Doris Cully; Tom Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Tian-Quan Cai; Sloan Stribling; Lee-Yuh Pai; Xiuying Ma; Joe Metzger; Andreas Verras; Daniel McMasters; Qing Chen; Elaine Tung; Wei Tang; Gino Salituro; Nicole Buist; Jeff Kuethe; Nelo Rivera; Joe Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Maxwell; Mike Lassman; Theresa McLaughlin; Jose Castro-Perez; Daphne Szeto; Gail Forrest; Richard Hajdu; Mark Rosenbach; Amjad Ali
Journal:  ACS Med Chem Lett       Date:  2015-04-07       Impact factor: 4.345

6.  Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry.

Authors:  A Grotevendt; H Wallaschofski; M Reincke; C Adolf; M Quinkler; M Nauck; W Hoffmann; R Rettig; A Hannemann
Journal:  Endocrine       Date:  2017-06-22       Impact factor: 3.633

Review 7.  Macrophage-mediated inflammation in metabolic disease.

Authors:  Ajay Chawla; Khoa D Nguyen; Y P Sharon Goh
Journal:  Nat Rev Immunol       Date:  2011-10-10       Impact factor: 53.106

Review 8.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 9.  The effect of RAAS blockade on the progression of diabetic nephropathy.

Authors:  Sara S Roscioni; Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Nat Rev Nephrol       Date:  2013-12-03       Impact factor: 28.314

Review 10.  Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.

Authors:  Sara S Roscioni; Dick de Zeeuw; Stephan J L Bakker; Hiddo J Lambers Heerspink
Journal:  Nat Rev Nephrol       Date:  2012-10-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.